Overdue and out of juice: post dates monitoring and
oligohydramniosGerry Marquette
Maternal Fetal MedicineBC Women’s Hospital
23rd Obstetrics Update for FPVancouver, October 2011
Objectives
• How we define overdue• When to start monitoring• How amniotic volumes are
measured and interpreted
Always use the proper name for things. Fear of a name increases fear of the thing itself.
Professor Albus Dumbledore,
to Harry Potter
Overdue
• Postterm: beyond 41 6/7 weeks or 293 days from LMP
• Postmaturity: dysmaturity (=IUGR in the term fetus)
• Post term= Prolonged pregnancy= post dates
Stillbirth rate in BC 2000-2009
0.0
1.0
2.0
3.0
4.0
5.0
6.0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Gestational age (weeks)
Stillbirths per 1,000
total births
Risk of stillbirth in BC
0.00.20.40.60.81.01.21.41.61.82.0
28 29 30 31 32 33 34 35 36 37 38 39 40 41 >=42
Gestational age (weeks)
Stillbirths per 1,000
fetuses a
t risk
Postterm morbidity
• Macrosomia/birth trauma• Meconium aspiration/NICU admission• Low Apgar/pH
Fetal/Neonatal
Maternal
C/S or assisted delivery
Increase in births at 41 weeks
• Decrease in births at 42 weeks• Increase in births at 41 weeks
When to start monitoring20 studies
Induction vs monitoring
• 41, 41 2/7,41 3/7, 42 weeks• Different methods of estimating gestational
age• Outcomes: perinatal mortality, morbidity
Canadian multi centre trialN=3407
Induction Monitor p OR
FetalDistress
10.3 % 12.8 % 0.017
Meconium 25 % 28.7 % 0.009
C/S 21.2 % 24.5 % 0.03 1.22 with CI=1.02-1.45
No diff in PNM and NN morbidityHannah M, N Engl J Med 1992;326:1587–92
Metaanalysis of prospective studies n=6588
Induce Monitor OR/CIC/S 20.1% 22% 0.88
0.78-0.99C/SAbn FHR
6.2% 8.0% 0.770.61-0.96
MeconiumStaining
22.4% 27.7% 0.750.66-0.84
Sanchez-Ramos Obstet Gynecol 2003;101:1312–8.
No diff in PNM and NN morbidity
Cochrane Metaanalysis of prospective studies n=5939
Induce Monitor RR/CIPNM 1/2986 9/2953 0.3
0.09-0.99C/S 23% 24.8% 0.92
0.76-1.12Meconiumaspiration
0.290.12-0.68
Cochrane Database Syst Rev 2006 Oct 18;(4):CD004945.
No diff in NN morbidity
Type and frequency of testing
• NST, BPP, CST, Doppler, AFV• Only one RCT on type • RCT’s on induction vs monitoring:
start during week 41more than once a weekNST and AFI
RCT: method of fetal surveillance145 uncomplicated pts at 42 weeks• 1.Modified BPP: computerised CTG, AFI,
breathing, gross and fine mvts vs 2.NST/DVP
• Abn results 1= 45%• Abn results 2= 20%
OR 3.5; 99% CI 1.3–9.1 no diff in outcomes
• Abn AFV 1 vs 2: 44.4% vs. 15.1%: OR 4.5; 99% CI 1.6–12.8Alfirevic et al. Br J Obstet Gynaecol 1995;102:638–43.
Amniotic fluid assessmentPostterm BCWH
• Normal: 5-95 percentile• Moderate oligohydramnios: 2.5-5 perc• Severe oligohydramnios: <2.5 perc
Amniotic fluid assessmentPostterm BCWH
AFI and DVP
• Normal: AFI≥50 and DVP≥20• Moderate oligo: AFI<50 and DVP≥20• Severe oligo: DVP<20
Reducing pregnancies reaching 41 weeks
• Early scan• Membrane sweeping
RCT first vs second trimester u/s dating
First trimester U/SN=104
Second trimester U/SN=92
p RRCI
Redated41.3% 10.9% <0.001
0.260.15-0.46
Induction for postterm
5/104 12/92 0.01 0.370.14-0.96
Bennett at al AJOG 2004;190;1077
Postterm protocolBCWH
• Induction offered as of 41 3/7 weeks but no later than 42 weeks
• Fetal surveillance as of 41 weeksevery 3 days
• NST and AFI/DVP
Postterm protocolBCWH
• If NST and AFV are normal: repeat testing within 3 days
• If NST is atypical or abnormal, furthur monitoring done immediately following U/S (Doppler of UA added)
• If moderate oligo: offer induction or repeat testing within 2 days (Doppler added)
• If severe oligo present: delivery is highly suggested
Conclusion
• How we define overdue• When to start monitoring• How amniotic volumes are
measured and interpreted
Postterm protocolBCWH
NST/AFV normal:Repeat testing within 3 days
If NST Is atypical/abnormal:
Doppler addedImmediate furthur
monitoring
If moderate oligo:Doppler added
Suggest induction/delivery
Or retest within2 days
If severe oligo:Doppler added
Consider immedateInduction/delivery